CLOs on the Move

ViaCyte

www.viacyte.com

 
ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.viacyte.com
  • 3550 General Atomics Court
    San Diego, CA USA 92121
  • Phone: 858.207.0500

Executives

Name Title Contact Details
Marty Lorenzo
General Counsel Profile

Similar Companies

HemoShear Therapeutics

We are dedicated to discovering novel biological targets and developing drugs that profoundly improve the lives of people born with rare metabolic defects who are unable to sustain basic biochemical processes necessary for life.

Sionna Therapeutics

We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis.

Fytokem Products

Fytokem Products Inc. is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Vesigen Therapeutics

Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology.

EndGenitor Technologies

EndGenitor Technologies is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.